Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04688411 · ClinicalTrials.gov registry record · NA

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

A NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT04688411: Recruiting NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

NCT04688411 is a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 40 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04688411, a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.

Primary Outcome

Feasibility is defined as 70% of participants logging their daily HU 70% of the time over 12 weeks or 59 out of 84 study days. This will be reported as a dichotomous outcome, either yes or no.

Conditions Studied

Sickle Cell Disease Sickle Beta Zero Thalassemia Sickle B+ Thalassemia Sickle Cell Hemoglobin C

Interventions

  • BEHAVIORAL MED-Go App

Study Locations (1)

Illinois

  • Ann & Robert H Lurie Children's Hospital of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-09-28
Est. Completion 2025-02-01
Phase NA
Ann & Robert H Lurie Children's Hospital of Chicago

159 total trials

What NCT04688411 shows while recruiting

NCT04688411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (86% lower).

The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which MED-Go App is the first listed.

NCT04688411 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT04688411 about?

NCT04688411 is a clinical study titled "An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease". The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell...

What is the current status of trial NCT04688411?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2020-09-28. Estimated completion is 2025-02-01.

What conditions does trial NCT04688411 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C.

What interventions are being tested in trial NCT04688411?

The interventions under investigation include: MED-Go App (BEHAVIORAL).

Who is sponsoring clinical trial NCT04688411?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04688411 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04688411's enrollment target sits among peer trials

40 124th of 213 higher than 86 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04688411

Source: ClinicalTrials.gov NCT04688411, the US trial registry maintained by the National Library of Medicine. NCT04688411 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.